Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies C-POST Trial Eli Lilly Trials DeFi Trial DESTINY-Breast09 Trial Drug Efficacy SCORPIO-PEP Trial SURMOUNT-OSA Lecanemab Eli Lilly Brensocatib Clinical Trial EMBER-3 Trial Weight Loss Medications PURPOSE 2 Trial GSK Clinical Trial Be6A Lung-01 Trial ASPEN Trial BE HEARD Studies Eosinophilic Inflammation Management ADRIATIC Trial ASPEN Study SURMOUNT-OSA Study CagriSema INDIGO Trial E. coli Vaccine Trials STRIDE-3 Study Diazoxide Choline Extended-Release Cognitive Decline Efficacy and Safety Studies DREAMM Trials Immunotherapy Trials KEYNOTE-689 Trial ROSELLA Study BREAKWATER Trial Novo Nordisk Study Study Results MARIPOSA and FLAURA2 Trials Vaccine Efficacy CheckMate-067 Destiny-Breast09 Study RUBY Trial KEYNOTE-905/EV-303 Trial SERENA-6 ACHIEVE-1 Trial Weight Loss Drugs DREAMM-7 Trial VERITAC-2 Trial Placebo-Controlled Trials PURPOSE Trials TRONTIER Studies ADjoin Extension Trial Eli Lilly Studies H3 K27M-mutant Glioma ACROSS 2 Trial Weight Loss Studies Tonmya SEQUOIA and CLL14 Trials ESSENCE Trial EV-302 Trial Ecnoglutide Gepotidacin vs Nitrofurantoin Avexitide SUNMO Trial ACROSS 2 Study PATHFNDR Trials Clarity AD Trial Oasis Trials Osimertinib Study Eisai Co., Ltd. Analgesic Products Cytomegalovirus Vaccine Semaglutide 3475A-D77 Study IRAKLIA Trial Cagrilintide MOTION Study AURIGA Study STEP UP Trial Liver Disease Treatments PERSEUS and CEPHEUS Trials LIBERTY-CUPID Program KEYNOTE-689 ASC4FIRST Trial SOLARIS Trial Brepocitinib Antibody Therapy PROTOSTAR Study DESTINY-Breast12 Study IMforte Trial Oncology Trials HER2CLIMB-05 Trial FIBRONEER-IPF Trial DESTINY-Breast05 Trial KAI-9531 Navenibart Clinical Development DURAVYU Trials C-POST Study REGENCY Trial FLAURA2 Study STAMP Trial

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

Merck plans to seek FDA review in early 2026 based on these Phase 3 lipid-lowering results.

Oral PCSK9 Pill Enlicitide Cuts LDL Up to 60% in Phase 3 Trial

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

Oral Semaglutide 25 mg Shows Larger Metabolic Gains With At Least 15% Weight Loss in OASIS-4

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

FDA Approves Gazyva for Adults With Active Lupus Nephritis

Adjuvant Pembrolizumab Cuts Risk of Distant Metastases in Merkel Cell Carcinoma at ESMO 2025

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

FDA Approves Glaukos’ Epioxa, First Epithelium-On Corneal Cross-Linking Therapy in the U.S.

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

Veradermics Advances Long-Acting Oral Minoxidil Into Phase 3 U.S. Trials

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma